Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 782 participants.
Also called NCT03900026
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 782 participants
- Registry
-
NCT03900026
-
- Other papers using this trial's data
- Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, Hungary
- Registry status
- Completed
Technical summary
Registry record NCT03900026. Randomized; quadruple masking; primary purpose prevention. Start 2019-05-30 (actual); primary completion 2025-01-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
- Acronym
- NEWTON-CABG
- Condition
- Coronary Artery Bypass Graft Surgery
- Condition
- Atherosclerosis
- Condition
- Vein Occlusion
- Intervention (Drug)
- Evolocumab
- Intervention (Other)
- Placebo
- Lead sponsor
- Unity Health Toronto
- Collaborator
- Applied Health Research Centre
Record details
- Record id
cardio:ct-nct03900026- Content hash
fea01e46208819a5bf1d4e4bd079dfe9fe47c7b307a440e411ea2a357d15823c